Targets › GRIK2
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Nov 2026.
Ionotropic glutamate receptor that functions as a cation-permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system (By similarity). (UniProt, Q13002)
Open in Phaseline: the race on GRIK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| UniQure Biopharma | AAV9-hSyn1-miGRIK2 (AMT-260) AAV9 gene therapy delivering miRNA to silence GRIK2 and suppress GluK2-containing kainate | GRIK2 | Phase 1 | Mesial Temporal Lobe Epilepsy | Nov 2026 |
Mesial Temporal Lobe Epilepsy (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.